INT347182

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.23
First Reported 2007
Last Reported 2011
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 3
Disease Relevance 5.60
Pain Relevance 0.84

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (TNFAIP3) peptidase activity (TNFAIP3) nucleus (TNFAIP3)
DNA binding (TNFAIP3) ligase activity (TNFAIP3) cytoplasm (TNFAIP3)
Anatomy Link Frequency
A20 2
TNFAIP3 (Homo sapiens)
Pain Link Frequency Relevance Heat
Adalimumab 100 95.80 Very High Very High Very High
Etanercept 9 93.72 High High
Infliximab 9 93.12 High High
spinal inflammation 118 92.96 High High
alcohol 15 82.08 Quite High
Arthritis 21 81.76 Quite High
Inflammation 20 73.84 Quite High
methotrexate 3 73.44 Quite High
cINOD 29 5.00 Very Low Very Low Very Low
Pain 15 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Cancer 56 100.00 Very High Very High Very High
Epstein-barr Virus 170 98.96 Very High Very High Very High
Hodgkin's Disease 438 97.92 Very High Very High Very High
Apoptosis 4 93.00 High High
Seronegative Spondarthritis 127 92.96 High High
Arthritis 19 81.76 Quite High
Uveitis 5 74.80 Quite High
Inflammatory Bowel Disease 2 73.84 Quite High
Latex Hypersensitivity 1 57.68 Quite High
Disease 74 51.12 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Finally, TNFAIP3 is a tumor suppression gene that encodes for A20, a tumor suppressing protein.
Negative_regulation (suppressing) of TNFAIP3 in A20 associated with cancer
1) Confidence 0.23 Published 2011 Journal Advances in Hematology Section Body Doc Link PMC2994062 Disease Relevance 2.50 Pain Relevance 0
Finally, TNFAIP3 is a tumor suppression gene that encodes for A20, a tumor suppressing protein.
Negative_regulation (suppressing) of A20 in A20 associated with cancer
2) Confidence 0.20 Published 2011 Journal Advances in Hematology Section Body Doc Link PMC2994062 Disease Relevance 2.46 Pain Relevance 0
Substantial decreases in primary and secondary endpoints such as the BASDAI, ASAS20, ASAS40, ASAS5/6, and partial remission response criteria have suggested that the benefit achieved with adalimumab is at least comparable to that seen with etanercept and infliximab.
Negative_regulation (decreases) of ASAS20 associated with infliximab, adalimumab and etanercept
3) Confidence 0.01 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012440 Disease Relevance 0.63 Pain Relevance 0.84

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox